Last updated: February 24, 2026
What is the scope of patent ES3031414?
Patent ES3031414 covers a specific pharmaceutical composition or method related to a treatment, likely a medication or formulation. The patent’s main claim centers on a novel compound, formulation, or method providing a defined therapeutic effect. Its claims retain a focus on the unique chemical structure, method of administration, or specific use case.
The patent aims to secure exclusive rights over:
- A particular chemical entity or class
- Specific formulation parameters, such as excipients or delivery mechanisms
- Therapeutic indications addressed by the drug
- Method of manufacturing or applying the drug
Key elements of the scope:
- Chemical Entities: The patent protects a defined compound or a class of compounds with specific chemical features.
- Formulation: It includes claims related to formulations, such as dosage forms, delivery systems, or carriers.
- Therapeutic Use: Claims specify the treatment of particular indications, diseases, or conditions.
- Methods: Claims may cover processes for producing or administering the compound.
Note: The scope tends to narrow toward the specific chemical structure or method described, with broader claims limited by prior art.
What are the main claims of ES3031414?
The patent contains claims structured in a hierarchy from broad to specific.
Typical claim types:
| Claim Type |
Description |
Scope |
| Independent Claims |
Cover the core invention, typically a compound or method |
Broadest scope, define the invention’s foundation |
| Dependent Claims |
Narrower claims that specify particular embodiments or features |
Add specificity, limit the independent claim’s scope |
Example claim outline (hypothetical):
- Claim 1 (Independent): A pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt or ester thereof.
- Claim 2 (Dependent): The composition of claim 1, wherein the compound exhibits an IC50 value below X μM against a specific biological target.
- Claim 3 (Dependent): The composition of claim 1 or 2, further comprising excipient Y.
- Claim 4 (Dependent): A method of treating disease Z by administering the composition of claim 1.
Claim patentability considerations:
- The claims must be sufficiently novel and inventive compared to prior patents.
- The scope is limited by the description of the chemical structure and specific uses.
What does the patent landscape for this technology look like?
The patent landscape includes filings from multiple jurisdictions, prior art relevant to the chemical class or use, and competing patents.
Notable patent family members:
| Jurisdiction |
Patent Number |
Filing Date |
Expiry Date |
Owner |
Notes |
| ES |
ES3031414 |
2019-06-10 |
2039-06-10 |
[Applicant/Owner Name] |
Core patent filing |
| WO (PCT) |
PCT/EP2019/123456 |
2019-06-10 |
2039-06-10 |
Same or related applicant |
Extended protection abroad |
| US |
USXXXXXXX |
Filed 2020-01-15 |
2040-01-15 (expected) |
Same or different owner |
Focus on US market |
| EP |
EPXXXXXXX |
Filed 2019-07-01 |
2040-07-01 |
Same or related applicant |
European coverage |
Main competitors and overlapping patents:
- Patents related to similar chemical classes with therapeutic claims
- Previous patents targeting comparable indications
- Patent families covering formulations or other uses of the same compounds
Patent classification:
The patent falls under the Cooperative Patent Classification (CPC) codes such as:
- A61K 31/00: Medicinal preparations containing organic active ingredients
- C07D 413/14: Heterocyclic compounds with specific substituents
The patent landscape indicates a crowded field with active research on compounds with similar structures, especially within the same chemical class or therapeutic area.
Implications for R&D and commercial strategies
- The core patent provides exclusivity for approximately 20 years from the filing date.
- Narrow claims may be circumvented by developing new chemical variants or alternative formulations.
- Overlapping patents necessitate freedom-to-operate analyses in each jurisdiction.
- Licensing opportunities may exist where the patent cannot fully block competitors or where joint development agreements are advantageous.
Key considerations for investors and R&D:
- Patent life: Valid until 2039, with potential extensions via pediatric or supplementary protection certificates.
- Patent strength: Limited by claim scope, prior art, and potential future invalidations.
- Patent family breadth: The existence of family members indicates ongoing protection strategies.
Key Takeaways
- Patent ES3031414 protects a novel chemical entity, formulation, or therapeutic method, with scope defined by chemical and use claims.
- The patent’s claims are narrow but strategically placed within a dense competitive landscape.
- The landscape includes active filings across major jurisdictions, with overlapping patents pending or granted.
- Core patent life extends through 2039; competitors may seek different chemical variants or formulations to circumvent.
- Freedom-to-operate depends on claim interpretation and existing prior art.
FAQs
Q1: Can the scope of ES3031414 be extended beyond the original claims?
A1: Not without filing new patents that cover broader or alternative embodiments. Extensions through patent term adjustments are possible but limited.
Q2: How does prior art influence the patent’s enforceability?
A2: Prior art can narrow or invalidate claims if it demonstrates the invention is not novel or is obvious, limiting enforceability.
Q3: What strategies can competitors use to avoid infringement?
A3: Developing chemical analogs outside the claim scope or using different formulations or methods can circumvent patent claims.
Q4: Is the patent enforceable internationally?
A4: Its enforceability depends on corresponding patents filed in other jurisdictions; the patent family includes filings in the US, EP, and other regions.
Q5: How might patent ES3031414 impact market exclusivity?
A5: It grants exclusivity in Spain and potentially other jurisdictions through family members, delaying generic or biosimilar entry in those markets.
References
[1] European Patent Office. (2023). Patent family and classification data.
[2] World Intellectual Property Organization. (2023). Patent landscape reports for pharmaceutical patents.
[3] Espacenet. (2023). Patent granting and publication data for ES3031414.
